Magnoflorine inhibits cisplatin-induced protective autophagy by down-regulating HMGB1 and increases drug sensitivity in drug-resistant ovarian cancer cells

Abstract

Ovarian cancer (OC) is a prevalent type of gynecologic malignancy, and to improve its treatment effectiveness, it is essential to identify new and more potent therapeutic drugs. Magnoflorine is a fundamental chlorine alkaloid with various pharmacological properties, including anti-diabetic and anti-inflammatory effects. However, whether Magnoflorine can inhibit the protective autophagy induced by cisplatin by modulating (high-mobility group B1) HMGB1 requires further investigation. This study aims to assess the impact of Magnoflorine on cisplatin resistance in OC. Our findings demonstrate that Magnoflorine enhances the sensitivity of OC cells to cisplatin. Additionally, it promotes apoptosis in cisplatin-resistant OC cells and simultaneously inhibits cisplatin-induced protective autophagy. Mechanistically, Magnoflorine reduces HMGB1 expression in cisplatin-resistant OC cells. Collectively, these results suggest that Magnoflorine has potential as a therapeutic agent for cisplatin-resistant OC in future clinical applications.